The Digital Health Future of Oncology

It’s in the early morning of April 15th, 2030 that when looking at your smart mirror, the latter beeps a warning notification: that new mole on your chin should be checked by your dermatologist. That was to be expected. After all your genetic test revealed that you possess a mutation in the CDKN2A gene. But you also get the recommendation to have your esophagus and stomach checked as your connected smart scale registered a noticeable drop in weight and this mutation also carries an increased risk of gastrointestinal (GI) tract cancer. With such increased awareness and early stage diagnosis methods, will the cancer death rate decline further come 2030? How will oncology differ in the future for both physicians and patients? Source: At-home diagnosis Now that you’ve been made aware of those risks, you take a close up shot of that mole and send it to your dermatologist via your phone for further investigation. Following this you then connect to a gastroenterologist through the same telemedicine service provider like InTouch Health to inquire about preventive measures regarding your GI tract; after all, uncle John did succumb to colorectal cancer. Given your background, the doctor determines that she needs to visually assess your GI tract before coming to any conclusions. As such, she prescribes you the latest PillCam, a high resolution pill-sized camera that records and takes pictures which it transmits in real time as i...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine Personalized Medicine cancer digital health cancer treatment digital technology oncology cancer research cancer care digital health technologies Source Type: blogs

Related Links:

Authors: Matan D, Löfström U, Corovic Cabrera C, Eriksson B, Ekström M, Hage C, Ljunggren G, Lyngå P, Wallén H, Knudsen Malmqvist K, Linde C, Persson H Abstract OBJECTIVES: Heart failure (HF) management is suboptimal in Sweden despite available evidence-based guidelines. To improve HF treatment, a comprehensive HF management program (4D project) was implemented in the Stockholm County (>2.1 million inhabitants). Design. A standardized care program centralized at five hospital-based HF clinics was implemented in 2014-2017. We registered from 2012 to 2017: (1) numbers of referrals and v...
Source: Scandinavian Cardiovascular Journal - Category: Cardiology Tags: Scand Cardiovasc J Source Type: research
CONCLUSIONS: While none of described methods enables the simultaneous measurement of all microcirculatory parameters, certain techniques are widely used in arterial hypertension research, while others gain popularity in screening. PMID: 32969283 [PubMed - as supplied by publisher]
Source: Blood Pressure - Category: Hematology Tags: Blood Press Source Type: research
CONCLUSION: Optic nerve infiltration in systemic metastatic retinal lymphoma may have initial occult signs but with profound visual loss. Ocular infections like CMV retinitis and tuberculosis may mask and delay the diagnosis in immunocompromised patients. PMID: 32967510 [PubMed - as supplied by publisher]
Source: Ocular Immunology and Inflammation - Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research
Conclusion: Continuous COC was associated with increased BMD in women with POI compared to low-dose HT, with similar improvement in the COC and high-dose HT groups. Video Summary:
Source: Menopause - Category: OBGYN Tags: Original Studies Source Type: research
Selective estrogen receptor modulators (SERMs) are an increasingly important therapeutic modality that are used by clinicians on a daily basis. Unfortunately, clinicians have a limited understanding regarding the underlying mechanism(s) of how SERMs function and their increasingly useful role in the treatment of estrogen-responsive target tissues such as the breast, bone, vagina, uterine endometrium, and brain. This review will provide a basic understanding of our current knowledge of SERM pharmacodynamics and will highlight the clinical applications of Food and Drug Administration–approved SERMs in the treatment of ...
Source: Menopause - Category: OBGYN Tags: Clinical Corner: Invited Review Source Type: research
Conclusions and Relevance: Lacking strong evidence indicating significant patient risk for vaginal laser treatment of GSM, the FDA safety communication appears unsubstantiated and implies gender bias. Identified complications suggest most reported “adverse events” represent lack of treatment effect. The well-documented benefits and low risk of adverse event suggest laser therapy for GSM is reasonable with appropriate pretreatment counseling. Additional randomized, well-controlled clinical trials are needed to further elucidate both the safety and efficacy of this nonhormone therapy.
Source: Menopause - Category: OBGYN Tags: Review Articles Source Type: research
This study aimed to assess the symptom burden in the last 6 months of life in a real-world cohort. METHODS: Patients diagnosed with metastatic gynaecologic malignancies from 2016 to 2019 who completed the revised Edmonton Symptom Assessment System (ESASr) questionnaire within 6 months of death in a large Canadian province were identified. Patient-reported symptom scores were categorized as none to mild (0-3) and moderate to severe (4-10). Individual symptoms were subsequently grouped into physical, psychological, and total subscores. The severity of symptoms was further analyzed for any associations with age, time to d...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research
Publication date: 26 September–2 October 2020Source: The Lancet, Volume 396, Issue 10255Author(s): Andrew W Horne, Katy Vincent, Catherine A Hewitt, Lee J Middleton, Magda Koscielniak, Wojciech Szubert, Ann M Doust, Jane P Daniels, Suraiya Abdi, Santanu Acharya, Shamma Al-Inizi, Elizabeth Ball, Andrew Baranowski, Nadia Bhal, Kalsang Bhatia, Siladitya Bhattacharya, Judy V. Birch, Tyrone Carpenter, Tony Chalhoub, Ying C. Cheong
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 24 September 2020Source: Pharmacology &TherapeuticsAuthor(s): Kristen Fousek, Lucas A. Horn, Claudia Palena
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Authors: Shen GN, Li J, Jin YH, Sun HN, Hao YY, Jin MH, Liu R, Li WL, Zhang YQ, Yu JB, Yu NN, Wang WD, Yu LY, Kim JS, Kwon T, Han YH Abstract The aim of the present study was to verify the pro-apoptotic anticancer potential of several 5,8-dimethoxy-1,4-phthoquinone (DMNQ) derivatives in Ras-mediated tumorigenesis. MTT assays were used to detect cellular viability and flow cytometry was performed to assess intracellular reactive oxygen species (ROS) levels and apoptosis. The expression levels of proteins were detected via western blotting. Among the 12 newly synthesized DMNQ derivatives, 2-benzylthio-5,8-dimethoxyna...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
More News: Back Pain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Chronic Pain | Colorectal Cancer | Databases & Libraries | Dermatology | Environmental Health | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Information Technology | Internet | Pain | PET Scan | Radiology | Skin | Thyroid | Thyroid Cancer | Warnings